Johnson & Johnson

NYSE:JNJ  
168.50
+0.76 (+0.45%)
Earnings Announcements

J&J, On Covid-19 Says Like Many Organizations, We Are Evaluating Potential Benefit Of A Human Challenge Trials

Published: 09/23/2020 20:20 GMT
Johnson & Johnson (JNJ) - J&j, on Covid-19 Says Like Many Organizations, We Are Evaluating Potential Benefit of a Human Challenge Trials.
J&j, on Covid-19 Vaccine Says Will Only Conduct a Human Challenge Trial in a Situation in Which It Was Deemed Ethical to Do So by Ethical Committees.
Revenue is expected to be $22.52 Billion
Adjusted EPS is expected to be $2.29

Next Quarter Revenue Guidance is expected to be $23.45 Billion
Next Quarter EPS Guidance is expected to be $2.40

More details on our Analysts Page.